Infantile Spasm (West Syndrome)-Pipeline Review, H2 2016

Infantile Spasm (West Syndrome)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8797IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Infantile Spasm (West Syndrome)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Syndrome)-Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Nervous System) pipeline landscape.

Infantile spasms are a type of epilepsy with a characteristic age of onset (typical age when seizures start), pattern of seizures and electroencephalogram (EEG). Symptoms include typical pattern is of a sudden flexion (bending forward) in a tonic (stiffening) fashion of the body, arms and legs. Sometimes, the episodes are different, with the arms and legs being flung outwards (these are called 'extensor' spasms). Causes include central nervous system infections, abnormal brain development or injury, genetic abnormalities (Down syndrome, Miller-Dieker syndrome) and metabolic disorders (mitochondrial diseases, phenylketonuria, and hypoglycemia). Treatment includes antiepileptic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Infantile Spasm (West Syndrome)-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.Infantile Spasm (West Syndrome).

Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Infantile Spasm (West Syndrome) Overview 6

Therapeutics Development 7

Pipeline Products for Infantile Spasm (West Syndrome)-Overview 7

Infantile Spasm (West Syndrome)-Therapeutics under Development by Companies 8

Infantile Spasm (West Syndrome)-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Infantile Spasm (West Syndrome)-Products under Development by Companies 11

Infantile Spasm (West Syndrome)-Companies Involved in Therapeutics Development 12

Anavex Life Sciences Corp 12

Catalyst Pharmaceuticals Inc 13

GW Pharmaceuticals Plc 14

INSYS Therapeutics Inc 15

Novartis AG 16

Retrophin Inc 17

Infantile Spasm (West Syndrome)-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

ANAVEX-273-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AVL-5189-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

cannabidiol-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

cannabidiol-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

cosyntropin-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

cosyntropin ER-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CPP-115-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

JBPOS-0101-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Infantile Spasm (West Syndrome)-Dormant Projects 52

Infantile Spasm (West Syndrome)-Product Development Milestones 53

Featured News & Press Releases 53

Sep 19, 2016: Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports 53

Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms 53

Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) 54

May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms 54

Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD 55

Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 55

Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms 56

Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 56

Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115 57

Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia 58

Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome 58

Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference 59

Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry 60

Dec 13, 2011: Catalyst Starts Phase Ia Safety Study For CPP-115 60

Dec 02, 2011: Catalyst To Present Data On CPP-115 At American Epilepsy Society's 65th Annual Meeting 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Top 10 Targets, H2 2016 19

Number of Products by Stage and Top 10 Targets, H2 2016 19

Number of Products by Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

List of Tables

Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Infantile Spasm (West Syndrome)-Pipeline by Anavex Life Sciences Corp, H2 2016 12

Infantile Spasm (West Syndrome)-Pipeline by Catalyst Pharmaceuticals Inc, H2 2016 13

Infantile Spasm (West Syndrome)-Pipeline by GW Pharmaceuticals Plc, H2 2016 14

Infantile Spasm (West Syndrome)-Pipeline by INSYS Therapeutics Inc, H2 2016 15

Infantile Spasm (West Syndrome)-Pipeline by Novartis AG, H2 2016 16

Infantile Spasm (West Syndrome)-Pipeline by Retrophin Inc, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Infantile Spasm (West Syndrome)-Dormant Projects, H2 2016 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anavex Life Sciences Corp, Catalyst Pharmaceuticals Inc, GW Pharmaceuticals Plc, INSYS Therapeutics Inc, Novartis AG, Retrophin Inc

Infantile Spasm (West Syndrome) Therapeutic Products under Development, Key Players in Infantile Spasm (West Syndrome) Therapeutics, Infantile Spasm (West Syndrome) Pipeline Overview, Infantile Spasm (West Syndrome) Pipeline, Infantile Spasm (West Syndrome) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com